KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Debt to Equity (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Debt to Equity for 16 consecutive years, with $2.12 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 35.81% year-over-year to $2.12, compared with a TTM value of $2.12 through Dec 2025, down 35.81%, and an annual FY2025 reading of $2.12, down 35.81% over the prior year.
  • Debt to Equity was $2.12 for Q4 2025 at Teva Pharmaceutical Industries, down from $2.31 in the prior quarter.
  • Across five years, Debt to Equity topped out at $3.31 in Q4 2024 and bottomed at $2.05 in Q4 2021.
  • Average Debt to Equity over 5 years is $2.47, with a median of $2.44 recorded in 2023.
  • The sharpest move saw Debt to Equity soared 35.61% in 2024, then plummeted 35.81% in 2025.
  • Year by year, Debt to Equity stood at $2.05 in 2021, then increased by 20.38% to $2.47 in 2022, then fell by 1.07% to $2.44 in 2023, then soared by 35.61% to $3.31 in 2024, then tumbled by 35.81% to $2.12 in 2025.
  • Business Quant data shows Debt to Equity for TEVA at $2.12 in Q4 2025, $2.31 in Q3 2025, and $2.52 in Q2 2025.